BR0213939A - Amidas de ácido antranìlico e uso farmacêutico das mesmas - Google Patents

Amidas de ácido antranìlico e uso farmacêutico das mesmas

Info

Publication number
BR0213939A
BR0213939A BR0213939-1A BR0213939A BR0213939A BR 0213939 A BR0213939 A BR 0213939A BR 0213939 A BR0213939 A BR 0213939A BR 0213939 A BR0213939 A BR 0213939A
Authority
BR
Brazil
Prior art keywords
alkyl
alkenyl
formula
treatment
alkynyl
Prior art date
Application number
BR0213939-1A
Other languages
English (en)
Portuguese (pt)
Inventor
Guido Bold
Pascal Furet
Paul William Manley
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of BR0213939A publication Critical patent/BR0213939A/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/28Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton
    • C07C237/40Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton having the nitrogen atom of the carboxamide group bound to a carbon atom of a six-membered aromatic ring
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/06Antiglaucoma agents or miotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36Radicals substituted by singly-bound nitrogen atoms
    • C07D213/38Radicals substituted by singly-bound nitrogen atoms having only hydrogen or hydrocarbon radicals attached to the substituent nitrogen atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/89Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to the ring nitrogen atom

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pulmonology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
  • Reproductive Health (AREA)
  • Obesity (AREA)
  • Oncology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Indole Compounds (AREA)
BR0213939-1A 2001-11-08 2002-11-07 Amidas de ácido antranìlico e uso farmacêutico das mesmas BR0213939A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0126901.8A GB0126901D0 (en) 2001-11-08 2001-11-08 Organic compounds
GBGB0212917.9A GB0212917D0 (en) 2001-11-08 2002-06-05 Organic compounds
PCT/EP2002/012445 WO2003040101A1 (en) 2001-11-08 2002-11-07 Anthranilic acid amides and pharmaceutical use thereof

Publications (1)

Publication Number Publication Date
BR0213939A true BR0213939A (pt) 2004-08-31

Family

ID=26246753

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0213939-1A BR0213939A (pt) 2001-11-08 2002-11-07 Amidas de ácido antranìlico e uso farmacêutico das mesmas

Country Status (25)

Country Link
US (1) US7067543B2 (OSRAM)
EP (2) EP2269988B1 (OSRAM)
JP (1) JP4179989B2 (OSRAM)
KR (1) KR100633814B1 (OSRAM)
CN (1) CN100467450C (OSRAM)
AR (1) AR037261A1 (OSRAM)
AT (1) ATE494278T1 (OSRAM)
AU (1) AU2002342889B2 (OSRAM)
BR (1) BR0213939A (OSRAM)
CA (1) CA2462390C (OSRAM)
DE (1) DE60238856D1 (OSRAM)
GB (2) GB0126901D0 (OSRAM)
HR (1) HRP20040412A2 (OSRAM)
IL (1) IL161163A0 (OSRAM)
MX (1) MXPA04004390A (OSRAM)
MY (1) MY136322A (OSRAM)
NO (1) NO326986B1 (OSRAM)
NZ (1) NZ532587A (OSRAM)
PE (1) PE20030540A1 (OSRAM)
PL (1) PL368417A1 (OSRAM)
PT (1) PT1446381E (OSRAM)
RS (1) RS29404A (OSRAM)
RU (1) RU2315756C2 (OSRAM)
TW (1) TWI260985B (OSRAM)
WO (1) WO2003040101A1 (OSRAM)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7307088B2 (en) * 2002-07-09 2007-12-11 Amgen Inc. Substituted anthranilic amide derivatives and methods of use
GB0229022D0 (en) * 2002-12-12 2003-01-15 Novartis Ag Organic Compounds
UA89035C2 (ru) 2003-12-03 2009-12-25 Лео Фарма А/С Эфиры гидроксамовых кислот и их фармацевтическое применение
IN240644B (OSRAM) * 2004-01-28 2010-05-28 Mitsui Chemicals Inc
DE102004009238A1 (de) * 2004-02-26 2005-09-08 Merck Patent Gmbh Arylamid-Derivate
JPWO2006070878A1 (ja) * 2004-12-28 2008-06-12 アステラス製薬株式会社 カルボン酸誘導体またはその塩
EP2145873A1 (fr) * 2008-06-17 2010-01-20 Commissariat A L'energie Atomique Nouveaux composés ayant une activité protectrice vis-à-vis de l'action de toxines et de virus au mode d'action intracellulaire
PA8840701A1 (es) 2008-08-27 2010-04-21 Leo Pharma As NUEVO RECEPTOR VEGF-2 e INHIBIDORES DE PROTEÍNAS TIROSINA QUINASA Y SU USO FARMACÉUTICO DE LOS MISMOS
JP2011057661A (ja) * 2009-08-14 2011-03-24 Bayer Cropscience Ag 殺虫性カルボキサミド類

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3226394A (en) * 1964-06-16 1965-12-28 Shulton Inc Pyridylethylated anthranilamides and derivatives thereof
CA2155662A1 (en) * 1993-12-27 1995-07-06 Fumihiro Ozaki Anthranilic acid derivative
GB9511694D0 (en) * 1995-06-09 1995-08-02 Fujisawa Pharmaceutical Co Benzamide derivatives
AU4779897A (en) 1996-10-02 1998-04-24 Novartis Ag Fused pyrazole derivatives and processes for their preparation
TW523506B (en) * 1996-12-18 2003-03-11 Ono Pharmaceutical Co Sulfonamide or carbamide derivatives and drugs containing the same as active ingredients
US6140351A (en) * 1997-12-19 2000-10-31 Berlex Laboratories, Inc. Ortho-anthranilamide derivatives as anti-coagulants
GB9824579D0 (en) * 1998-11-10 1999-01-06 Novartis Ag Organic compounds

Also Published As

Publication number Publication date
CA2462390A1 (en) 2003-05-15
RS29404A (sr) 2007-02-05
US7067543B2 (en) 2006-06-27
HRP20040412A2 (en) 2005-06-30
RU2004117548A (ru) 2005-06-10
TWI260985B (en) 2006-09-01
PT1446381E (pt) 2011-01-31
CN1578768A (zh) 2005-02-09
KR20050044374A (ko) 2005-05-12
PE20030540A1 (es) 2003-08-05
KR100633814B1 (ko) 2006-10-13
EP2269988A3 (en) 2011-02-16
CA2462390C (en) 2011-01-11
EP1446381B1 (en) 2011-01-05
GB0126901D0 (en) 2002-01-02
CN100467450C (zh) 2009-03-11
TW200300086A (en) 2003-05-16
NZ532587A (en) 2006-02-24
MY136322A (en) 2008-09-30
EP2269988B1 (en) 2012-05-23
GB0212917D0 (en) 2002-07-17
PL368417A1 (en) 2005-03-21
DE60238856D1 (de) 2011-02-17
AR037261A1 (es) 2004-11-03
EP1446381A1 (en) 2004-08-18
ATE494278T1 (de) 2011-01-15
AU2002342889B2 (en) 2007-03-01
EP2269988A2 (en) 2011-01-05
NO326986B1 (no) 2009-03-30
RU2315756C2 (ru) 2008-01-27
US20040248947A1 (en) 2004-12-09
JP2005508382A (ja) 2005-03-31
IL161163A0 (en) 2004-08-31
NO20042137L (no) 2004-05-25
JP4179989B2 (ja) 2008-11-12
WO2003040101A1 (en) 2003-05-15
MXPA04004390A (es) 2005-05-16

Similar Documents

Publication Publication Date Title
BR0009507A (pt) Derivados de ftalazina para o tratamento de doenças inflamatórias
EA200900388A1 (ru) Бензоксазолы и оксазолопиридины, применимые в качестве ингибиторов киназ janus
CY1122765T1 (el) Ξηρανθεισα με ψεκασμο συνθεση αc220
WO2004071400A3 (en) Histone deacetylase inhibitors of novel benzamide derivatives with potent differentiation and anti-proliferation activity
DE60323090D1 (de) 1h-imidazoä4,5-cüchinolinderivate zur behandlung von protein kinase-abhängigen krankheiten
BR0011324A (pt) Agonista de adrenoceptores beta 2
MX2010002396A (es) Metodos para administrar n-(5-ter-butil-isoxazol-3-il)-n?-{4-[7-(2 -morfolin-4-il-etoxi)imidazo[2, 1-b][1,3]benzotiazol-2-il] fenil} urea para tratar enfermedaes proliferativas.
CY1107401T1 (el) Παραγωγα βενζοθειαζολιου πα την θεραπευτικη αντιμετωπιση της νοσου alzheimer και της νοσου parkinson
NO912410L (no) Fremgangsmaate for fremstilling av terapeutisk aktive heterocyklen-derivater.
NO20051263L (no) Ny anvendelse av benzotiazolderivater
BRPI0418074B8 (pt) derivado de amida, composição farmacêutica, inibidor da tirosina cinase bcr-abl e agentes terapêuticos
GB0126902D0 (en) Organic compounds
BR0213939A (pt) Amidas de ácido antranìlico e uso farmacêutico das mesmas
TR200101649T2 (tr) Piperazin türevleri.
CY1108004T1 (el) Χρηση r-αρυλοπροπιονικων οξεων για την παραγωγη φαρμακων για την αντιμετωπιση παθησεων σε ανθρωπους και ζωα, οι οποιες μπορουν να επηρεαστουν θepαπευτικα μεσω της αναστολης της ενepγοποιησης του nf-kb
ATE367387T1 (de) Verwendung von oxindolderivaten zur behandlung von mit demenz in zusammenhang stehenden krankheiten, alzheimer-krankheit und mit glycogensynthasekinase-3 assoziierten leiden
ES2164109T3 (es) Derivados de n-(3-piperidinilcarbonil)-beta-alanina como antagonistas de paf.
ES2139673T3 (es) Utilizacion de norastemizol para el tratamiento de rinitis alergica.
BR9913377A (pt) Composto derivado de aminoálcool
DE60226225D1 (de) Phtalazine derivate mit angiogenesis inhibierender wirkung
BR0308719A (pt) Composto e sais e solvatos deste, processo para a preparação do mesmo, método de tratamento de um paciente humano ou animal que sofre ou é suscetìvel a uma condição inflamatória, e, composição farmacêutica
BR0317292A (pt) Derivados de amida de ácido antranìlico e seu uso farmacêutico
TH88080A (th) แอนทรานิลิกแอซิดเอไมด์และการใช้งานทางเภสัชกรรมของมัน
TH88080B (th) "แอนทรานิลิกแอซิดเอไมด์และการใช้งานทางเภสัชกรรมของมัน"
ECSP045091A (es) Amidas de acido antranilico y uso farmaceutico de las mismas

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08L Patent application lapsed because of non payment of annual fee [chapter 8.12 patent gazette]

Free format text: REFERENTE AO NAO RECOLHIMENTO DAS 10A E 11A ANUIDADES.

B08I Publication cancelled [chapter 8.9 patent gazette]

Free format text: ANULADA A PUBLICACAO CODIGO 8.12 NA RPI NO 2258 DE 15/04/2014 POR TER SIDO INDEVIDA.

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 10A, 11A, 12A, 13A, 14A, 15A, 16A, 17A E 18A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2602 DE 17-11-2020 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.